Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
79 hedge funds and large institutions have $195M invested in Concert Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 16 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
7% less funds holding
Funds holding: 85 → 79 (-6)
18% less capital invested
Capital invested by funds: $239M → $195M (-$44.2M)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less call options, than puts
Call options by funds: $572K | Put options by funds: $1.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.01M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$5.14M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.35M |
| 4 |
QI
QS Investors
New York
|
+$1.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.07M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.95M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$2.28M |
| 4 |
PC
Paulson & Co
New York
|
-$1.2M |
| 5 |
AIC
AWM Investment Company
New York
|
-$1.17M |
CNCE Hedge Fund Activity: Q2 2017 in Review
79 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2017, worth a combined $195M — down 18% from $239M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CNCE and 12 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 26 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $7.01M. The largest seller was BVF Inc, cutting an estimated $7.07M.
- 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2017, down from 85 in Q1 2017.
- Funds reported $195M of Concert Pharmaceuticals, Inc. stock for Q2 2017, down 18% quarter-over-quarter.
- 12 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2017 and 16 closed out, a net change of -4 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2017 was Citadel Advisors, an estimated $7.01M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2017 was BVF Inc, an estimated $7.07M sold.
Based on aggregated 13F filings for Q2 2017.